IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor or Other Solid Tumor

Inclusion Criteria: * Histologically confirmed solid tumor * Relapsed or refractory disease * No central nervous system (CNS) tumor or lymphoma * Histological confirmation may have been made at original diagnosis or at relapse * Current disease state must be one for which there is no known curative therapy or therapy proven to prolong survival with an acceptable quality of life * Measurable or evaluable disease * Patients with Ewing sarcoma/peripheral primitive neuroectodermal tumor (PNET) must have tissue blocks or slides available * Study chair must be notified if tissue blocks or slides are not available * Karnofsky performance status (PS) ≥ 50% (patients \> 10 years of age) and Lansky (PS) ≥ 50% (patients ≤ 10 years of age) * Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score * Creatinine clearance or radioisotope GFR ≥ 70 mL/min OR serum creatinine based on age/gender as follows: * 1 to \< 2 years (males and females 0.6 mg/dL) * 2 to \< 6 years (males and females 0.8 mg/dL) * 6 to \< 10 years (males and females 1.0 mg/dL) * 10 to \< 13 years (males and females 1.2 mg/dL) * 13 to \< 16 years (males 1.5 mg/dL and females 1.4 mg/dL) * ≥ 16 years (males 1.7 mg/dL and females 1.4 mg/dL) * Bilirubin ≤ 1.5 times upper limit of normal (ULN) for age * SGPT (ALT) ≤ 110 μ/L (for the purpose of this study, the ULN for SGPT is 45 μ/L) * Serum albumin ≥ 2 g/dL * Patients with known bone marrow metastatic disease will be eligible for study but not evaluable for hematologic toxicity * Patients must not be known to be refractory to red cell or platelet transfusion * Patients with solid tumors without bone marrow involvement must meet the following criteria: * Peripheral absolute neutrophil count ≥ 1,000/μL * Platelet count ≥ 100,000/μL (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment) * Hemoglobin ≥ 8.0 g/dL (may receive RBC transfusions) * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 3 months after completion of study therapy * No uncontrolled infection * No known type I or type II diabetes mellitus * Able to comply with the safety monitoring requirements of the study, in the opinion of the investigator * No history of allergic reactions attributed to compounds of similar chemical or biologic composition to IMC-A12 * Fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study * At least 7 days since prior and no concurrent hematopoietic growth factors * Growth factors that support platelet or white cell number or function can only be administered for culture-proven bacteremia or invasive fungal infection * At least 7 days since prior and no concurrent biologic antineoplastic agents * At least 6 weeks since prior monoclonal antibodies * At least 3 months since prior total body irradiation (TBI), craniospinal external radiotherapy (XRT), or ≥ 50% radiotherapy to the pelvis * At least 2 weeks since prior local XRT (small port) * At least 6 weeks since other prior substantial bone marrow radiotherapy * More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosourea) * More than 7 days since prior and no concurrent systemic corticosteroids * Prior stem cell transplant or rescue allowed provided there has been no evidence of active graft-versus-host-disease within the past 2 months * No prior monoclonal antibody therapy targeting the IGF-IR * No concurrent chemotherapy, radiotherapy, or immunotherapy * No concurrent anticancer agents * No concurrent insulin or growth hormone therapy * No other concurrent investigational drugs